BLK vs JNJ: Which Is the Better Buy?
Side-by-side comparison of BlackRock, Inc. and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-22.
BlackRock, Inc. · Financial Services
$1,042.85
+125.5% upside to fair value
Grade A
High Quality
VS
Johnson & Johnson · Healthcare
$230.69
+14.0% upside to fair value
Grade C
High Quality
QuantHub Verdict
BLK has more upside to fair value
(+125.5%).
BLK trades at a lower forward P/E
(25.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
BLK |
JNJ |
| Current Price |
$1,042.85 |
$230.69 |
| Fair Value Estimate |
$2,351.12 |
$263.05 |
| Upside to Fair Value |
+125.5%
|
+14.0%
|
| Market Cap |
$162.2B |
$555.9B |
| Forward P/E |
25.9x
|
26.8x
|
| EV / EBITDA |
16.9x
|
18.5x
|
| Price / Sales |
6.3x
|
5.8x
|
| Price / FCF |
45.2x
|
28.2x
|
| Revenue Growth YoY |
+28.3%
|
+9.9%
|
| Gross Margin |
59.1%
|
69.1%
|
| Operating Margin |
29.9%
|
26.9%
|
| Return on Equity |
12.0%
|
26.5%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.21%
|
3.54%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
BlackRock, Inc. is the world's largest asset manager with over $14 trillion in assets under management, operating primarily in financial services and asset management. The company benefits from a durable competitive moat driven by its scale, technology platform Aladdin, and founder-led management with CEO Laurence D. Fink at the helm since inception. BlackRock exhibits strong fundamentals includi…
Johnson & Johnson is a leading healthcare company focused on pharmaceuticals and medical devices following its consumer health spin-off. The business quality is high due to its durable competitive moat, diversified portfolio, and strong management with deep institutional knowledge. Despite a 52.4% decline in earnings in the most recent quarter, revenue grew 9.9% year-over-year in the same period,…
Accumulation Zones
| Metric |
BLK |
JNJ |
| Zone Low |
$1,763.34 |
$197.29 |
| Zone High |
$1,998.45 |
$223.59 |
| In Buy Zone? |
Yes
|
No
|